Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

View All Documentation

A5922

Sigma-Aldrich

Amifostine trihydrate

≥97% (TLC), powder

Synonyme(s) :

2-(3-Aminopropyl)aminoethyl phosphorothioate, WR2721

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C5H15N2O3PS · 3 H2O
Numéro CAS:
112901-68-5
Poids moléculaire :
268.27
Numéro MDL:
MFCD00453866
Code UNSPSC :
12352200
ID de substance PubChem :
24278231
Nomenclature NACRES :
NA.77

Niveau de qualité

200

Pureté

≥97% (TLC)

Forme

powder

Température de stockage

2-8°C

Chaîne SMILES 

OP(SCCNCCCN)(O)=O.O.O.O

InChI

1S/C5H15N2O3PS.3H2O/c6-2-1-3-7-4-5-12-11(8,9)10;;;/h7H,1-6H2,(H2,8,9,10);3*1H2

Clé InChI

TXQPXJKRNHJWAX-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Amifostine may provide renal protection during PRRT using somatostatin analogs by mitigating radiation damage and reducing the absorbed kidney radiation dose. Amifostine remediates the degenerative effects of radiation on the mineralization capacity of the murine mandible.

Actions biochimiques/physiologiques

Radioprotective agent. Selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy. Selectivity is due to preferential uptake by normal tissues and subsequent metabolic activation to 2-(3-aminopropyl)aminoethanethiol.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ourania Nicolatou-Galitis et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 21(1), 357-364 (2012-10-12)
The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. A systematic
Melanie Duval et al.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 41(5), 309-315 (2012-10-25)
The effectiveness of amifostine in the prevention of cisplatin ototoxicity remains controversial. The objective of this meta-analysis was to determine whether amifostine is successful in preventing ototoxicity secondary to cisplatin chemotherapy. Meta-analysis. We conducted a systematic review of all randomized
Henry L Gómez et al.
Hematology/oncology and stem cell therapy, 5(3), 152-157 (2012-10-26)
We report the 8-year follow-up of 34 patients aged ≥69 years old with NHL included in a phase IIb open-label randomized parallel groups study to evaluate the effectiveness of amifostine in preventing the toxicity of cyclophosphamide, doxorubicin, vincristine and prednisone
Murat Caloglu et al.
Journal of cancer research and therapeutics, 8(2), 260-265 (2012-07-31)
The aim of the study was to compare the protective efficacy of l-carnitine (LC) to amifostine on radiation-induced acute small intestine damage. Thirty, 4-week-old Wistar albino rats were randomly assigned to four groups - Group 1: control (CONT, n =
Michael I Koukourakis et al.
International journal of radiation oncology, biology, physics, 85(1), e7-13 (2012-10-09)
Postmastectomy radiation therapy (PMRT) provides major local control and survival benefits. More aggressive radiation therapy schemes may, however, be necessary in specific subgroups, provided they are safely administered. We report the tolerance and efficacy of a highly accelerated and hypofractionated
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique